Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2011-12-27
Solola, Taofiq A (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S464000
Reexamination Certificate
active
08084494
ABSTRACT:
The present invention concerns substituted aminophenylsulfonamide compounds, their use as protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present substituted aminophenylsulfonamide compounds with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.
REFERENCES:
patent: 2004/0039016 (2004-02-01), Ghosh et al.
patent: WO 96/22275 (1996-07-01), None
patent: WO 99/33792 (1999-07-01), None
patent: WO 99/33793 (1999-07-01), None
patent: WO 99/33795 (1999-07-01), None
patent: WO 99/33815 (1999-07-01), None
patent: WO 99/67254 (1999-12-01), None
patent: WO 03/049746 (2003-06-01), None
patent: WO 03/090690 (2003-11-01), None
Augustijns, P., et al. “Drug Absorption Studies of Prodrug Esters using the Caco-2 Model: Evaluation of Ester Hydrolysis and Transepithelial Transport”, International Journal of Pharmaceutics, vol. 166 (1998) pp. 45-53.
Chou and Talalay, “Quantitative Analysis of dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors”, Advanced Enzyme Regulations, vol. 22 (1984) pp. 27-55.
Hertogs, K., et al. “A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs”, Antimicrobial Agents and Chemotherapy, vol. 42, No. 2 (1998) pp. 269-276.
Cross, L.C., et al., “Rules for the Nomenclature of Organic Chemistry Section E: Stereochemistry”, Pure and Applied Chemistry, vol. 45, (1976), pp. 11-30.
Goodman and Gilman, “The Pharmacological Basis of therapeutics”, Eighth Edition, Chapter 11, (1990) “Biotransformation of Drugs”, pp. 13-15.
Meyer, S., et al., “TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates”, Antimicrobial Agents and Chemotherapy, vol. 49, No. 6, (2005), pp. 2314-2321.
International Search Report mailed Feb. 26, 2007 for corresponding Application No. PCT/EP2006/068993.
Boonants Paul Jozef Gabriel Maria
De Kock Herman Augustinus
Jonckers Tim Hugo Maria
Last Stefaan Julien
Surleraux Dominique Louis Nestor Ghislain
Solola Taofiq A
Tibotec Pharmaceuticals Ltd.
LandOfFree
Substituted aminophenylsulfonamide compounds as HIV protease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted aminophenylsulfonamide compounds as HIV protease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted aminophenylsulfonamide compounds as HIV protease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293408